Meet the Newest SU2C Dream Teams: Lung and Ovarian Cancer
Posted on April 20, 2015, 12:00 AM
At SU2C, one of our ongoing missions is to unite and fund incredible groups of scientists, to tackle some of the biggest problems in both cancer treatment and prevention. As a part of our Dream Teams, leaders from across disciplines, institutions, countries and specialties come together to collaborate and work to move their research quickly to patients in need.
Thanks to donors like you and incredible collaborators, SU2C was able to announce the selection of two new Dream Teams at the American Association of Cancer Research (AACR) annual meeting on Monday, April 20th 2015: an Ovarian Cancer Dream Team and a Lung Cancer Dream Team.
We are thrilled to introduce you to both teams and give you a first look into their work.
Ovarian Cancer Dream Team At-A-Glance
Approximately 22,000 women in the US are diagnosed with ovarian cancer every year, and 14,000 die of the disease. This Dream Team aims to change these frightening statistics. The collaboration among all three major ovarian cancer groups in the United States marks the first time they have collaborated on a single research initiative.
The team will focus on two major interventions: one is therapy and the other is ovarian cancer prevention. “Ovarian cancer is so deadly, we are excited that this Dream Team will bring patient benefits not only in potential new treatments, but in developing a new approach to genetic testing and counseling,” said SU2C president and CEO Sung Poblete, PhD, RN.
Meet the SU2C-OCRF-OCNA-NOCC Ovarian Cancer Dream Team:
Lung Cancer Dream Team At-A-Glance
Lung cancer is the leading cause of cancer deaths in both men and women. It is an epidemic that needs more research and better treatments now. SU2C is proud to join forces with the American Cancer Society to form the new SU2C-American Cancer Lung Cancer Dream Team, supported by a significant Bristol-Meyers Squibb donation to Stand Up To Cancer.
The team will focus on combining targeted therapies with immunotherapy to attack the number one cancer killer in America. “One of our goals in supporting this Dream Team is to get new therapies to lung cancer patients quickly. We are pleased to see that this team has already begun planning and will launch eight new clinical trials in the first year of its grant,” said Otis Brawley, M.D., chief medical officer of ACS.
Meet the SU2C-ACS Lung Cancer Dream Team:
Meet the Rest of the SU2C Dream Teams
These two teams alongside our other SU2C funded scientists are working hard to get better treatments to patients faster than ever before. Thank you for supporting them and bringing us one step closer to a world where everyone diagnosed with cancer survives.
To learn more about the rest of the SU2C Dream Teams and Translational Research Teams click here.
Return to Blog
- I’m Hopeful Because of Immunotherapy and Cancer Research
- Reflecting on the 2017 Early Age Onset Colorectal Cancer Symposium
- SU2C Co-Founder Noreen Fraser (1953 – 2017)
- Breast Cancer Can Happen to Men Too
- Research Teams Share Progress at the 2017 Summit
- Finding Purpose By Helping Others Fight Cancer
- The Great Escape: Tumor-Suppressor Genes and Male-Female Cancer Disparity
- What Life Looks Like After Cancer
- Survivor Contestant Adam Klein Shares His Story
- Don’t Say “Cancer” & Other Thoughts From a Three-Time Survivor